Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Sep;90(9):1016–1025. doi: 10.1111/j.1349-7006.1999.tb00850.x

A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors

Yukio Nihei 1,✉, Yasuyo Suga 1, Yoshihiro Morinaga 1, Kazuo Ohishi 1, Akira Okano 1, Koji Ohsumi 1, Toshihiro Hatanaka 1, Ryusuke Nakagawa 1, Takashi Tsuji 1, Yukio Akiyama 1, Sachiko Saito 2, Katsuyoshi Hori 2, Yasufumi Sato 2, Takashi Tsuruo 3
PMCID: PMC5926154  PMID: 10551333

Abstract

AC‐7700, a novel combretastatin A‐4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated the antitumor activity of AC‐7700 on solid tumors in two experimental models, an advanced tumor model (murine colon 26 (c26) adenocarcinoma, colon 38 (c38) adenocarcinoma, MethA fibrosarcoma, Sarcoma 180 (S180), Lewis lung carcinoma (3LL), human LS180 adenocarcinoma) and an orthotopically transplanted tumor model (c26), compared with that of cisplatin (CDDP). The maximum tolerable dose (MTD) of CDDP suppressed early‐stage c26 and c38 tumor growth when treatment was started after the tumor volume (TV) reached 0.2–0.5 cm3, but it showed reduced activity against the same tumors at an advanced growth stage when TV exceeded 2 cm3. At its MTD, AC‐7700 was active against all tumors tested except 3LL in both early and advanced growth stages, reducing the tumor mass and having a curative effect in advanced c38 tumors. AC‐7700 was also effective on orthotopically transplanted c26 tumors, showing a comparable activity to that on subcutaneous tumors. Unlike flavon acetic acid, which damages tumor vasculature by inducing endogenous tumor necrosis factor‐α production, AC‐7700 potently suppressed the growth of advanced c26 tumors in athymic as well as euthymic mice. These results suggest that AC‐7700 is a novel antivascular agent that may have potent activity against advanced‐stage cancer in the clinical setting.

Keywords: Combretastatin, Tubulin‐binding agent, Advanced solid tumor, Orthotopic transplantation, Host immune status

Full Text

The Full Text of this article is available as a PDF (136.6 KB).

REFERENCES

  • 1).Hori , K. , Suzuki , M. , Tanda , S. and Saito , S.Characterization of heterogeneous distribution of tumor blood flow in the rat . Jpn. J. Cancer Res. , 82 , 109 – 117 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2).Hori , K. , Suzuki , M. , Tanda , S. , Saito , S. , Shinozaki , M. and Zhang , Q.‐H.Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II‐induced hypertension . Cancer Res. , 52 , 912 – 916 ( 1992. ). [PubMed] [Google Scholar]
  • 3).Jain , R. K.Transport of molecules in the tumor interstitium: a review . Cancer Res. , 47 , 3039 – 3051 ( 1987. ). [PubMed] [Google Scholar]
  • 4).Horsman , M. R. , Chaplin , D. J. and Overgaard , J.The use of blood flow modifiers to improve the treatment response of solid tumors . Radiother. Oncol. , 20 ( Suppl. ), 47 – 52 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 5).Suzuki , M. , Hori , K. , Abe , I. , Saito , S. and Sato , H.Anew approach to cancer chemotherapy: selective enhancement of tumor blood flow with Angiotensin II . J. Natl. Cancer Inst. , 67 , 663 – 669 ( 1981. ). [PubMed] [Google Scholar]
  • 6).Carswell , E. A. , Old , L. J. , Kassel , R. L. , Green , S. , Fiore , N. and Williamson , B.An endotoxin‐induced serum factor which causes necrosis of tumors . Proc. Natl. Acad. Sci. USA , 72 , 3666 – 3670 ( 1975. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7).Mahadevan , V. , Malik , S. T. A. , Meager , A. , Fiers , W. , Lewis , G. P. and Hart , I. R.Role of tumor necrosis factor in flavone acetic acid‐induced tumor vasculature shutdown . Cancer Res. , 50 , 5537 – 5542 ( 1990. ). [PubMed] [Google Scholar]
  • 8).Pratesi , G. , Rodolfo , M. , Rovetta , G. and Parmiani , G.Role of T cells and tumor necrosis factor in antitumor activity and toxicity of flavon acetic acid . Eur. J. Cancer , 26 , 1079 – 1083 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 9).Yang , D. , Satoh , M. , Ueda , H. , Tsukagoshi , S. and Yamazaki , M.Activation of tumor‐infiltrating macro‐phages by a synthetic lipid A analog (ONO‐4007. and its implication in antitumor effects . Cancer Immunol. Immunother. , 38 , 287 – 293 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10).Dvorak , H. F. and Gresser , I.Microvascular injury in pathogenesis of interferon‐induced necrosis of subcutaneous tumor in mice . J. Natl. Cancer Inst. , 81 , 497 – 502 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 11).Belardelli , F. , Proietti , E. , Ciolli , V. , Sestili , P. , Carpinelli , G. , Vito , M. D. , Ferretti , A. , Woodrow , D. , Boraschi , D. and Podo , F.Interleukin‐1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti‐tumor effects of tumor necrosis factor alpha or beta . Int. J. Cancer , 44 , 116 – 123 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 12).Yanase , T. , Tamura , M. , Fujita , K. , Kodama , S. and Tanaka , K.Inhibitory effect of angiogenesis inhibitor TNP‐470 on tumor growth and metastasis of human cell lines in vitro and in vivo . Cancer Res. , 53 , 2566 – 2570 ( 1993. ). [PubMed] [Google Scholar]
  • 13).Yamaoka , M. , Yamamoto , T. , Masaki , T. , Ikeyama , S. , Sudo , K. and Fujita , T.Inhibition of tumor and metastasis of rodent tumors by the angiogenesis inhibitor O‐(chloro‐acetyl‐carbamoyl)fumagillol (TNP‐470; AGM‐1470) . Cancer Res. , 53 , 4262 – 4267 ( 1993. ). [PubMed] [Google Scholar]
  • 14).Gutterman , J. and Kavanagh , J.A phase I study of the toxicity, pharmacokinetics, and activity of TNP‐470 administered to patients with advanced or recurrent squamous cell cancer of the cervix . Proc. Am. Soc. Clin. Oncol. , 14 , 281 ( 1995. ). [Google Scholar]
  • 15).Fotsis , T. , Zhang , Y. , Pepper , M. S. , Adlercreutz , H. , Montesano , R. , Nawroth , P. P. and Schweigerer , L.The endogenous oestrogen metabolite 2‐methoxyoestradiol inhibits angiogenesis and suppresses tumor growth . Nature , 368 , 237 – 239 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 16).Boehm , T. , Folkman , J. , Browder , T. and O'Reilly , M. S.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance . Nature , 390 , 404 – 407 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 17).O'Reilly , M. S. , Holmgren , L. , Chen , C. and Folkman , J.Angiostatin induces and sustains dormancy of human primary tumors in mice . Nat. Med. , 2 , 689 – 692 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 18).Sim , B. K. L. , O'Reilly , M. S. , Liang , H. , Fortier , A. H. , He , W. , Madsen , J. W. , Lapcevich , R. and Nacy , C. A.A recombinant human Angiostatin protein inhibits experimental primary and metastatic cancer . Cancer Res. , 57 , 1329 – 1334 ( 1997. ). [PubMed] [Google Scholar]
  • 19).Hieber , U. and Heim , M. E.Tumor necrosis factor for the treatment of malignancies . Oncology , 51 , 142 – 153 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 20).Feinberg , B. , Kurzorck , R. , Talpaz , M. , Blick , M. , Saks , S. and Gutterman , J. U.Phase I trial of intravenously‐administered recombinant tumor necrosis factor‐alpha in cancer patients . J. Clin. Oncol. , 6 , 1328 – 1334 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 21).Kerr , D. J. , Maughan , T. , Newlands , E. , Rustin , G. , Bleehen , N. M. , Lewis , C. and Kaye , S. B.Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma . Br. J. Cancer , 60 , 104 – 106 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22).Siegenthaler , P. , Kaye , S. B. , Monfardini , S. and Renard , J.Phase II trial with flavon acetic acid (NSC. 347512, LM975. in patients with non‐small cell lung cancer . Ann. Oncol. , 3 , 169 – 170 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 23).Gradisher , W. J.An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action . Invest. New Drugs , 15 , 49 – 59 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 24).Pluda , J. M. , Wyvill , K. , Figg , W. D. , Whitcup , S. M. , Lietzau , J. , Saville , M. W. , Cohen , R. , Feigal , E. , Parks , D. , Foli , A. , Bailey , J. , Broder , S. and Yarchoan , R.A phase I study of an angiogenesis inhibitor, TNP‐470 (AGM‐1470), administered to patients with HIV‐associated Kaposi's sarcoma . Proc. Am. Soc. Clin. Oncol. , 13 , 51 ( 1994. ). [Google Scholar]
  • 25).Zukiwski , A. , Gutterman , J. , Bui , C. , Sella , A. , Ellerhorst , J. , Tu , S. , Amato , R. , Figg , W. , Kilboum , R. and Logothetis , C.Phase I trial of the angiogenesis inhibitor TNP‐470 (AGM‐1470. in patients with androgen independent prostate cancer . Proc. Am. Soc. Clin. Oncol. , 13 , 252 ( 1994. ). [Google Scholar]
  • 26).Kudelka , A. , Edwards , C. , Freedman , R. , Girtanner , R. , Kaplan , A. , Fishman , A. , Balat , O. , Tresukosol , D. , De Leon , C. G. , Hord , M. , Finnegan , M. , Calayag , M. , Hunter , C. , Gutterman , J. and Kavanagh , J.A phase I study of the toxicity, pharmacokinetics, and activity of TNP‐470 administered to patients with advanced or recurrent squamous cell cancer of the cervix . Proc. Am. Soc. Clin. Oncol. , 14 , 281 ( 1995. ). [Google Scholar]
  • 27).Chaplin , D. J. , Pettit , G. R. , Parkins , C. S. and Hill , S. A.Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents . Br. J. Cancer , 74 ( Suppl. XXVII ), S86 – S88 ( 1996. ). [PMC free article] [PubMed] [Google Scholar]
  • 28).Hill , S. A. , Sampson , L. E. and Chaplin , D. J.Anti‐vascular approaches to solid tumor therapy: evaluation of Vinblastine and flavone acetic acid . Int. J. Cancer , 63 , 119 – 123 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 29).Dark , G. G. , Hill , S. A. , Prise , V. E. , Tozer , G. M. , Pettit , G. R. and Chaplin , D. J.Combretastatin A‐4, an agent that displays potent and selective toxicity toward tumor vasculature . Cancer Res. , 10 , 1829 – 1834 ( 1997. ). [PubMed] [Google Scholar]
  • 30).Nihei , Y. , Suzuki , M. , Okano , A. , Tsuji , T. , Akiyama , Y. , Saito , S. , Hori , K. and Sato , Y.Anti‐vascular effects of AC‐7700 on solid tumors; comparison with other tubulin binding agents . Proc. Am. Assoc. Cancer Res. , 39 , 324 ( 1998. ). [Google Scholar]
  • 31).Ohsumi , K. , Nakagawa , R. , Fukuda , Y. , Hatanaka , T. , Morinaga , Y. , Nihei , Y. , Ohishi , K. , Suga , Y. , Akiyama , Y. and Tsuji , T.Novel combretastatin analogues effective against murine solid tumors; design and structure‐activity relationships . J. Med. Chem. , 41 , 3022 – 3032 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 32).Nihei , Y. , Suga , Y. , Morinaga , Y. , Ohishi , K. , Suzuki , M. , Okano , A. , Ohsumi , K. , Nakagawa , R. , Tsuji , T. , Akiyama , Y. and Tsuruo , T.A novel combretastatin‐A4 derivative AC‐7700 shows marked antitumor activity against advanced solid tumors . Proc. Am. Assoc. Cancer Res. , 39 , 1143 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33).Huang , X. , Molema , G. , King , S. , Watkins , L. , Edgington , T. S. and Thorpe , P. E.Tumor infarction in mice by antibody‐directed targeting of tissue factor to tumor vasculature . Science , 275 , 547 – 550 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 34).Denekamp , J. , Hill , S. A. and Hobson , B.Vascular occlusion and tumor cell death . Eur. J. Cancer Clin. Oncol. , 19 , 271 – 275 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 35).Yamamura , H. and Sato , H.Quantitative studies on the developing vascular system of rat hepatoma . J. Natl. Cancer Inst. , 53 , 1229 – 1240 ( 1974. ). [DOI] [PubMed] [Google Scholar]
  • 36).Field , S. B. , Needham , S. , Burney , I. A. , Maxwell , R. J. , Coggle , J. E. and Griffiths , J. R.Differences in vascular response between primary and transplanted tumors . Br. J. Cancer , 63 , 723 – 726 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37).Fu , X. , Besterman , J. M. , Monosov , A. and Hoffman , R. M.Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens . Proc. Natl. Acad. Sci. USA , 88 , 9345 – 9349 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38).Togo , S. , Shimada , H. , Kubota , T. , Moossa , A. R. and Hoffman , R. M.Host organ specifically determines cancer progression . Cancer Res. , 55 , 681 – 684 ( 1995. ). [PubMed] [Google Scholar]
  • 39).Bibby , M. C. , Phillips , R. M. , Double , J. A. and Pratesi , G.Anti‐tumor activity of flavone acetic acid (NSC 347512. in mice – influence of immune status . Br. J. Cancer , 63 , 57 – 62 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40).Ching , L.‐M. , Joseph , W. R. and Baguley , B. C.Antitumor responses to flavone‐8‐acetic acid and 5, 6‐dimethylxan‐thenone‐4‐acetic acid in immune deficient mice . Br. J. Cancer , 66 , 128 – 130 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41).Baguley , B. C. , Holdaway , K. M. , Thomsen , L. L. , Zhuang , L. and Zwi , L. J.Inhibition of growth of colon38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism . Eur. J. Cancer , 27 , 482 – 487 ( 1991. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES